摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

β-Aethyl-β-phenyl-alanin | 110973-00-7

中文名称
——
中文别名
——
英文名称
β-Aethyl-β-phenyl-alanin
英文别名
2-amino-3-phenyl-valeric acid;2-Amino-3-phenyl-valeriansaeure;2-amino-3-ethyl-3-phenylpropanoic acid;2-Amino-3-phenylpentanoic acid
β-Aethyl-β-phenyl-alanin化学式
CAS
110973-00-7
化学式
C11H15NO2
mdl
——
分子量
193.246
InChiKey
VGHSTKSUXOSXQU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.7
  • 重原子数:
    14
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    63.3
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Method and compositions for identifying anti-HIV therapeutic compounds
    申请人:GILEAD SCIENCES, INC.
    公开号:US20040121316A1
    公开(公告)日:2004-06-24
    Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.
    提供了一种鉴定含有羧酸酯或磷酸酯基团抗HIV治疗化合物的方法。可以选择使用新型酶GS-7340酯解酶筛选这类化合物的文库。还提供了与GS-7340酯解酶相关的组合物和方法。
  • Novel compounds and methods for synthesis and therapy
    申请人:——
    公开号:US20040053999A1
    公开(公告)日:2004-03-18
    Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.
    描述了新化合物。这些化合物通常包括一个酸性基团,一个碱性基团,一个取代基或N-酰基和一个具有可选择羟基化的烷基部分的基团。还描述了包括本发明的抑制剂的药物组合物。还描述了在疑似含有神经氨酸酶的样品中抑制神经氨酸酶的方法。还描述了抗原材料、聚合物、抗体、本发明化合物与标记物的结合物以及用于检测神经氨酸酶活性的测定方法。
  • Nitrile-containing enzyme inhibitors and ruthenium complexes thereof
    申请人:The Ohio State University Research Foundation
    公开号:US20140100173A1
    公开(公告)日:2014-04-10
    The invention provides nitrile-containing protease inhibitors caged to ruthenium compounds. The nitrile-caged ruthenium compounds provide inactivated inhibitors that can be delivered to surface or site for activation, for example, but exposure to light. The invention also provides methods for delivering protease inhibitors to subjects for the therapeutic treatment of conditions such as cancer.
    这项发明提供了与化合物结合的含腈基蛋白酶抑制剂。这些腈基蛋白酶抑制剂与化合物结合后形成失活的抑制剂,可以通过光照等方式被释放到表面或部位进行激活。该发明还提供了将蛋白酶抑制剂传递给受试者以治疗癌症等疾病的方法。
  • The asymmetric synthesis of allylglycine and other unnatural α-amino acids via zinc-mediated allylation of oximes in aqueous media
    作者:Stephen Hanessian、Rui-Yang Yang
    DOI:10.1016/0040-4039(96)01118-5
    日期:1996.7
    Enantiomerically pure or highly enriched allylglycine and its chain-substituted analogs are easily accessible from the reaction of the sultam derivative of O-benzyl glyoxylic acid oxime with allylic bromides in the presence of powdered zinc in aqueous ammonium chloride.
    对映体纯的或高度富集的烯丙基甘酸及其链取代的类似物,在粉末状的氯化铵溶液中的存在下,很容易从O-苄基乙醛酸磺胺生物与烯丙基的反应中获得。
  • Inhibitors of hepatitis C virus NS3 protease
    申请人:——
    公开号:US20020065248A1
    公开(公告)日:2002-05-30
    The present invention relates to compounds of Formula (I): 1 wherein A 1 is methylene, ethylene or propylene group and A 2 is N or CR 5 , or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    本发明涉及化合物的结构公式(I):其中A1为亚甲基、乙烯基丙烯基,A2为N或CR5,或其立体异构体形式、立体异构体混合物或药用盐形式,用作HCV NS3蛋白酶抑制剂,以及包含相同化合物的药物组合物和诊断试剂盒,以及用于治疗病毒感染或作为测定标准或试剂的方法。
查看更多